COVID-19 vaccines are at risk of being undermined by vaccine hesitancy. Pharma must take steps to ensure transparency in data monitoring committees and trial data to build public trust in vaccines.
Patients have a stake in the relationship between doctors and pharmaceutical companies, so the CMA's current review of its guidelines for doctor/pharma interactions is everybody’s business.
A bioethicist explains a recent report that recommends how to distribute a COVID-19 vaccine equitably.
With Donald Trump already doing a great job of making the public more wary of a coronavirus vaccine, big pharma has to do better than this.
A lot depends on China and India sharing the products of their pharmacuetical manufacturing with the rest of the world.
Drug companies normally use patents to protect new treatments.
Toilet paper shortages were bad enough. A shortage of drugs during the COVID-19 pandemic would be worse. A provision in the Canadian government's relief package aims to prevent that from happening.
Tax rates may be the same for big and small companies, but five charts show how things work out differently in practice.
Drug prices for many life-saving drugs have skyrocketed in recent years. The reasons may surprise you.
Gwyneth Paltrow's new Netflix series, The Goop Lab, raises serious questions about the spread of health misinformation as well as the conflict of interest the show represents.
Too often, pharmaceutical companies and device manufacturers exert influence in how their products are tested in the research phase and recommended in the clinic.
Drug companies have a job to do and so does Health Canada. When the relationship becomes murky, the public are at risk.
Every year, thousands of medical devices and drugs are recalled in the US. But the decision to recall a flawed product is often left up to the manufacturer.
OxyContin maker Purdue has reportedly been mulling a bankruptcy filling, just as the first of around 2,000 lawsuits against it prepares to go to trial.
Considered in historical context, Purdue's plan to peddle opioid addiction medicines to vulnerable people is not so surprising. Gilded-Age pharmaceutical companies used similar strategies.
Artificially intelligent drug design programs could discover new therapies for conditions that are difficult or prohibitively expensive to cure.
A new study reveals how many patient groups lobby for new drugs to be funded by public plans in Canada -- all while receiving funding from the companies manufacturing the drugs in question.
Clinical guidelines have a big impact on the care you receive and the drugs you're prescribed. But one in five doctors who write these guidelines have undisclosed ties to drug companies.
Evidence shows that opioid manufacturers fund patient advocacy groups in Canada, distorting policies to protect public health.
Developing drugs is typically the domain of large pharmaceutical companies. But here is an example of drug development for a rare pediatric brain cancer that was done in a university setting.